Professor Gavin Screaton was appointed to the Chair of Medicine at Imperial College in 2004. The Department of Medicine has recently been restructured and houses over 900 research and support staff with activities housed in 5 divisions: Brain Sciences; Infectious Diseases; Experimental Medicine; Diabetes, Endocrinology & Metabolism, and Immunology & Inflammation.
Professor Screaton received his first degree from Cambridge in 1984 before moving on to Oxford to complete his medical studies in 1987. He then completed training in General Internal medicine and obtained a DPhil from Oxford University in 1998. His research, which has been supported by a series of Fellowships awarded by the MRC and Wellcome Trust, has covered a variety of topics from control of RNA processing and apoptosis to immunology. The current interests of his laboratory revolve around the immunology of infectious diseases with a special interest in dengue haemorrhagic fever, where his research is currently funded by the MRC and Wellcome Trust, with active research collaborations in South-East Asia.
Professor Screaton is a Fellow of the Academy of Medical Sciences, a Fellow of the Royal College of Physicians, a member of the Association of Physicians and was made a Founder Senior Investigator in the National Institute for Health Research. He also sits on funding panels at the Wellcome Trust and MRC.
et al., 2016, MAIT cells are activated during human viral infections, Nature Communications, Vol:7, ISSN:2041-1723
et al., 2016, Remarkably low affinity of CD4/peptide-major histocompatibility complex class II protein interactions, Proceedings of the National Academy of Sciences of the United States of America, Vol:113, ISSN:0027-8424, Pages:5682-5687
et al., 2016, Association of Microvascular Function and Endothelial Biomarkers With Clinical Outcome in Dengue: An Observational Study., J Infect Dis, Vol:214, Pages:697-706
Yacoub S, Mongkolsapaya J, Screaton G, 2016, Recent advances in understanding dengue., F1000res, Vol:5
et al., 2016, Structural basis of potent Zika-dengue virus antibody cross-neutralization., Nature, Vol:536, Pages:48-53